BBNX Shareholder Alert: Beta Bionics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

Promise versus reality: the lawsuit contends Beta Bionics promoted "superior clinical outcomes" for its iLet insulin pump while a June 2025 FDA Form 483 documenting more than 18,000 unreported customer complaints stayed out of public view, and BBNX shares later fell roughly $23.09 from their Class Period high

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Beta Bionics, Inc. (NASDAQ: BBNX) that a class action has been filed on behalf of shareholders who purchased securities between July 30, 2025 and February 24, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.

BBNX traded at a Class Period high of $31.99 before falling to $20.14, a one-day drop of $11.85 (37%). Shares closed under $9.00 by April 10, 2026, a decline of approximately $23.09 per share (72%) that erased hundreds of millions of dollars in market capitalization. The Court has set November 3, 2026 as the deadline to apply for lead plaintiff appointment.

The Promise

On July 29, 2025, the Company projected confidence, telling investors the iLet "demands the least engagement from the user" and highlighting "the superior clinical outcomes of the iLet with our real-world data." In October 2025, management described the FDA's Form 483 as "primarily related to our customer complaint handling system" and said it did not "foresee any ongoing challenge with this at all."

The Reality

Results revealed a different picture, according to the lawsuit. The complaint contends the June 2025 Form 483 documented more than 18,000 unreported complaints among 29,419 iLet users, including reports of life-threatening hypoglycemia, and that no corrective actions were taken. On January 30, 2026, the Company disclosed an FDA Warning Letter citing non-conformities in its Quality Management System, Medical Device Reporting, and Correction and Removals.

The Numbers: Promised vs. Actual

• Promised: "superior clinical outcomes" supported by real-world data. Alleged reality: more than 18,000 customer complaints documented in a Form 483 covering fewer than 30,000 total users.
• Promised: an inspection finding limited to how a complaint is defined. Alleged reality: a 10-page FDA Warning Letter, publicly released February 24, 2026, citing systemic quality and reporting non-conformities.
• Promised: no "ongoing challenge" from the June 2025 inspection. Actual: a Warning Letter disclosed roughly three months after those assurances.
• Promised: growth in new iLet patient starts. Actual: an unexpected miss reported January 8, 2026, followed by the $11.85 single-day decline.
• Promised: a fully adaptive dosing algorithm. Alleged reality: an "extremely aggressive dosing algorithm" adopted after a built-in safety net was abandoned.
  
  

What the Lawsuit Alleges About the Gap

The gap demonstrates, as pleaded, that shareholders paid prices reflecting assurances rather than the regulatory record behind them.

"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. Here, the complaint alleges Beta Bionics promoted the iLet's real-world outcomes while a June 2025 FDA Form 483 identifying more than 18,000 unreported complaints remained undisclosed to shareholders." -- Joseph E. Levi, Esq.

Learn more about the case or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the BBNX Lawsuit

Q: What specific misstatements does the BBNX lawsuit allege? A: The complaint alleges Beta Bionics made materially false or misleading statements regarding the safety, efficacy, and regulatory standing of the iLet Bionic Pancreas, including characterizations of a June 2025 FDA Form 483 and the more than 18,000 unreported customer complaints it documented, during the Class Period. When the FDA Warning Letter and the underlying complaint data were disclosed, the stock price declined.

Q: When did Beta Bionics, Inc. allegedly mislead investors? A: The Class Period runs from July 30, 2025 to February 24, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the BBNX class action filed in? A: The case was filed in the United States District Court for the Central District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: What do BBNX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if my BBNX losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate as a class member.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.